Concomitant and bismuth quadruple regimens cleared ~90% of patients and outperformed triple therapy; sequential achieved ~84%. Adherence remained ~97% despite higher but manageable side effects.
Cohort of 198 coronary artery bypass grafting patients monitored for 1 year with insertable cardiac devices found high incidence of new-onset atrial fibrillation but minimal late burden.
With a number of major pharmaceutical shows, such as ACHEMA and CPHI, often taking place in Frankfurt, we gather up essential information on transport and what to do in the city after show hours.